Financhill
Sell
36

NONOF Quote, Financials, Valuation and Earnings

Last price:
$67.01
Seasonality move :
2.04%
Day range:
$67.00 - $70.08
52-week range:
$55.28 - $146.00
Dividend yield:
2.48%
P/E ratio:
19.85x
P/S ratio:
6.85x
P/B ratio:
14.82x
Volume:
2.8K
Avg. volume:
100.5K
1-year change:
-52.7%
Market cap:
$297.8B
Revenue:
$42.1B
EPS (TTM):
$3.38

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
NONOF
Novo Nordisk AS
$12B -- 23.24% -- --
ASND
Ascendis Pharma AS
$168.3M -$1.53 235.06% -62.7% $235.92
GLTO
Galecto
-- -$2.82 -- -51.46% $6.00
GMAB
Genmab AS
$909.4M $0.39 17.19% 7.82% $29.69
LLY
Eli Lilly and
$14.6B $5.54 34.58% 472% $952.27
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
NONOF
Novo Nordisk AS
$67.01 -- $297.8B 19.85x $1.14 2.48% 6.85x
ASND
Ascendis Pharma AS
$174.89 $235.92 $10.6B -- $0.00 0% 26.05x
GLTO
Galecto
$3.90 $6.00 $5.2M -- $0.00 0% --
GMAB
Genmab AS
$21.46 $29.69 $13.2B 12.76x $0.00 0% 4.50x
LLY
Eli Lilly and
$799.34 $952.27 $717.6B 65.04x $1.50 0.7% 14.73x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
NONOF
Novo Nordisk AS
46.15% 1.580 5.63% 0.54x
ASND
Ascendis Pharma AS
128.87% 0.160 9.75% 0.67x
GLTO
Galecto
-- 2.596 -- --
GMAB
Genmab AS
-- 0.135 -- 5.32x
LLY
Eli Lilly and
70.96% -0.134 5.19% 0.57x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
NONOF
Novo Nordisk AS
$9.2B $5.5B 53.78% 84.88% 54.06% $1.4B
ASND
Ascendis Pharma AS
$87.8M -$106M -59.13% -880.05% -48.32% -$15.8M
GLTO
Galecto
-- -$2.6M -- -- -- -$2.4M
GMAB
Genmab AS
$673M $188M 22.23% 22.23% 34.83% $257M
LLY
Eli Lilly and
$10.5B $5.4B 24.21% 78.25% 29.07% -$1.6B

Novo Nordisk AS vs. Competitors

  • Which has Higher Returns NONOF or ASND?

    Ascendis Pharma AS has a net margin of 37.18% compared to Novo Nordisk AS's net margin of -93.73%. Novo Nordisk AS's return on equity of 84.88% beat Ascendis Pharma AS's return on equity of -880.05%.

    Company Gross Margin Earnings Per Share Invested Capital
    NONOF
    Novo Nordisk AS
    83.49% $0.92 $37.3B
    ASND
    Ascendis Pharma AS
    82.65% -$1.66 $711.6M
  • What do Analysts Say About NONOF or ASND?

    Novo Nordisk AS has a consensus price target of --, signalling upside risk potential of 42.06%. On the other hand Ascendis Pharma AS has an analysts' consensus of $235.92 which suggests that it could grow by 34.9%. Given that Novo Nordisk AS has higher upside potential than Ascendis Pharma AS, analysts believe Novo Nordisk AS is more attractive than Ascendis Pharma AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    NONOF
    Novo Nordisk AS
    0 0 0
    ASND
    Ascendis Pharma AS
    12 0 0
  • Is NONOF or ASND More Risky?

    Novo Nordisk AS has a beta of 0.644, which suggesting that the stock is 35.566% less volatile than S&P 500. In comparison Ascendis Pharma AS has a beta of 0.376, suggesting its less volatile than the S&P 500 by 62.4%.

  • Which is a Better Dividend Stock NONOF or ASND?

    Novo Nordisk AS has a quarterly dividend of $1.14 per share corresponding to a yield of 2.48%. Ascendis Pharma AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk AS pays 43.71% of its earnings as a dividend. Ascendis Pharma AS pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios NONOF or ASND?

    Novo Nordisk AS quarterly revenues are $11B, which are larger than Ascendis Pharma AS quarterly revenues of $106.2M. Novo Nordisk AS's net income of $4.1B is higher than Ascendis Pharma AS's net income of -$99.6M. Notably, Novo Nordisk AS's price-to-earnings ratio is 19.85x while Ascendis Pharma AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 6.85x versus 26.05x for Ascendis Pharma AS. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NONOF
    Novo Nordisk AS
    6.85x 19.85x $11B $4.1B
    ASND
    Ascendis Pharma AS
    26.05x -- $106.2M -$99.6M
  • Which has Higher Returns NONOF or GLTO?

    Galecto has a net margin of 37.18% compared to Novo Nordisk AS's net margin of --. Novo Nordisk AS's return on equity of 84.88% beat Galecto's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    NONOF
    Novo Nordisk AS
    83.49% $0.92 $37.3B
    GLTO
    Galecto
    -- -$1.92 --
  • What do Analysts Say About NONOF or GLTO?

    Novo Nordisk AS has a consensus price target of --, signalling upside risk potential of 42.06%. On the other hand Galecto has an analysts' consensus of $6.00 which suggests that it could grow by 53.85%. Given that Galecto has higher upside potential than Novo Nordisk AS, analysts believe Galecto is more attractive than Novo Nordisk AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    NONOF
    Novo Nordisk AS
    0 0 0
    GLTO
    Galecto
    0 1 0
  • Is NONOF or GLTO More Risky?

    Novo Nordisk AS has a beta of 0.644, which suggesting that the stock is 35.566% less volatile than S&P 500. In comparison Galecto has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock NONOF or GLTO?

    Novo Nordisk AS has a quarterly dividend of $1.14 per share corresponding to a yield of 2.48%. Galecto offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk AS pays 43.71% of its earnings as a dividend. Galecto pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios NONOF or GLTO?

    Novo Nordisk AS quarterly revenues are $11B, which are larger than Galecto quarterly revenues of --. Novo Nordisk AS's net income of $4.1B is higher than Galecto's net income of -$2.5M. Notably, Novo Nordisk AS's price-to-earnings ratio is 19.85x while Galecto's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 6.85x versus -- for Galecto. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NONOF
    Novo Nordisk AS
    6.85x 19.85x $11B $4.1B
    GLTO
    Galecto
    -- -- -- -$2.5M
  • Which has Higher Returns NONOF or GMAB?

    Genmab AS has a net margin of 37.18% compared to Novo Nordisk AS's net margin of 27.27%. Novo Nordisk AS's return on equity of 84.88% beat Genmab AS's return on equity of 22.23%.

    Company Gross Margin Earnings Per Share Invested Capital
    NONOF
    Novo Nordisk AS
    83.49% $0.92 $37.3B
    GMAB
    Genmab AS
    94.13% $0.31 $5.3B
  • What do Analysts Say About NONOF or GMAB?

    Novo Nordisk AS has a consensus price target of --, signalling upside risk potential of 42.06%. On the other hand Genmab AS has an analysts' consensus of $29.69 which suggests that it could grow by 38.34%. Given that Novo Nordisk AS has higher upside potential than Genmab AS, analysts believe Novo Nordisk AS is more attractive than Genmab AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    NONOF
    Novo Nordisk AS
    0 0 0
    GMAB
    Genmab AS
    4 4 0
  • Is NONOF or GMAB More Risky?

    Novo Nordisk AS has a beta of 0.644, which suggesting that the stock is 35.566% less volatile than S&P 500. In comparison Genmab AS has a beta of 0.938, suggesting its less volatile than the S&P 500 by 6.249%.

  • Which is a Better Dividend Stock NONOF or GMAB?

    Novo Nordisk AS has a quarterly dividend of $1.14 per share corresponding to a yield of 2.48%. Genmab AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk AS pays 43.71% of its earnings as a dividend. Genmab AS pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios NONOF or GMAB?

    Novo Nordisk AS quarterly revenues are $11B, which are larger than Genmab AS quarterly revenues of $715M. Novo Nordisk AS's net income of $4.1B is higher than Genmab AS's net income of $195M. Notably, Novo Nordisk AS's price-to-earnings ratio is 19.85x while Genmab AS's PE ratio is 12.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 6.85x versus 4.50x for Genmab AS. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NONOF
    Novo Nordisk AS
    6.85x 19.85x $11B $4.1B
    GMAB
    Genmab AS
    4.50x 12.76x $715M $195M
  • Which has Higher Returns NONOF or LLY?

    Eli Lilly and has a net margin of 37.18% compared to Novo Nordisk AS's net margin of 21.68%. Novo Nordisk AS's return on equity of 84.88% beat Eli Lilly and's return on equity of 78.25%.

    Company Gross Margin Earnings Per Share Invested Capital
    NONOF
    Novo Nordisk AS
    83.49% $0.92 $37.3B
    LLY
    Eli Lilly and
    82.53% $3.06 $54.4B
  • What do Analysts Say About NONOF or LLY?

    Novo Nordisk AS has a consensus price target of --, signalling upside risk potential of 42.06%. On the other hand Eli Lilly and has an analysts' consensus of $952.27 which suggests that it could grow by 19.13%. Given that Novo Nordisk AS has higher upside potential than Eli Lilly and, analysts believe Novo Nordisk AS is more attractive than Eli Lilly and.

    Company Buy Ratings Hold Ratings Sell Ratings
    NONOF
    Novo Nordisk AS
    0 0 0
    LLY
    Eli Lilly and
    18 4 1
  • Is NONOF or LLY More Risky?

    Novo Nordisk AS has a beta of 0.644, which suggesting that the stock is 35.566% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.405, suggesting its less volatile than the S&P 500 by 59.528%.

  • Which is a Better Dividend Stock NONOF or LLY?

    Novo Nordisk AS has a quarterly dividend of $1.14 per share corresponding to a yield of 2.48%. Eli Lilly and offers a yield of 0.7% to investors and pays a quarterly dividend of $1.50 per share. Novo Nordisk AS pays 43.71% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios NONOF or LLY?

    Novo Nordisk AS quarterly revenues are $11B, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Novo Nordisk AS's net income of $4.1B is higher than Eli Lilly and's net income of $2.8B. Notably, Novo Nordisk AS's price-to-earnings ratio is 19.85x while Eli Lilly and's PE ratio is 65.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 6.85x versus 14.73x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NONOF
    Novo Nordisk AS
    6.85x 19.85x $11B $4.1B
    LLY
    Eli Lilly and
    14.73x 65.04x $12.7B $2.8B

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will Oklo Stock Double?
Will Oklo Stock Double?

Oklo (NYSE: OKLO) is only a year removed from its SPAC‑enabled debut,…

Why a $5 Stock Is Suddenly a Cash Machine
Why a $5 Stock Is Suddenly a Cash Machine

If you stopped tracking Grab Holdings (NASDAQ: GRAB) after its 2021 SPAC…

Is Roku Stock Undervalued Now?
Is Roku Stock Undervalued Now?

At roughly $89 a share, Roku (NASDAQ: ROKU) trades for barely…

Stock Ideas

Buy
69
Is NVDA Stock a Buy?

Market Cap: $4T
P/E Ratio: 56x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 43x

Sell
42
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 34x

Alerts

Buy
55
INKT alert for Jul 15

MiNK Therapeutics [INKT] is down 36.03% over the past day.

Sell
48
NEGG alert for Jul 15

Newegg Commerce [NEGG] is down 26.42% over the past day.

Buy
77
VBTX alert for Jul 15

Veritex Holdings [VBTX] is up 19.56% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock